RCSB PDB - 4W7P: Crystal Structure of ROCK 1 bound to YB-15-QD37 (original) (raw)
Novel ROCK inhibitors for the treatment of pulmonary arterial hypertension.
[Shaw, D.](/search?q=citation.rcsb%5Fauthors:Shaw, D.), [Hollingworth, G.](/search?q=citation.rcsb%5Fauthors:Hollingworth, G.), [Soldermann, N.](/search?q=citation.rcsb%5Fauthors:Soldermann, N.), [Sprague, E.](/search?q=citation.rcsb%5Fauthors:Sprague, E.), [Schuler, W.](/search?q=citation.rcsb%5Fauthors:Schuler, W.), [Vangrevelinghe, E.](/search?q=citation.rcsb%5Fauthors:Vangrevelinghe, E.), [Duggan, N.](/search?q=citation.rcsb%5Fauthors:Duggan, N.), [Thomas, M.](/search?q=citation.rcsb%5Fauthors:Thomas, M.), [Kosaka, T.](/search?q=citation.rcsb%5Fauthors:Kosaka, T.), [Waters, N.](/search?q=citation.rcsb%5Fauthors:Waters, N.), [van Eis, M.J.](/search?q=citation.rcsb%5Fauthors:van Eis, M.J.)
(2014) Bioorg Med Chem Lett 24: 4812-4817
PubMed: 25248678 Search on PubMed
PubMed Abstract:
A novel class of selective inhibitors of ROCK1 and ROCK2 has been identified by structural based drug design. PK/PD experiments using a set of highly selective Rho kinase inhibitors suggest that systemic Rho kinase inhibition is linked to a reversible reduction in lymphocyte counts. These results led to the consideration of topical delivery of these molecules, and to the identification of a lead molecule 7 which shows promising PK and PD in a murine model of pulmonary hypertension after intra-tracheal dosing.
Organizational Affiliation:
Novartis Horsham Research Centre, Wimblehurst Road, Horsham, West Sussex RH12 5AB, United Kingdom. Electronic address: duncan.shaw@novartis.com.